University of California San Francisco UCSF Medical CenterUCSF Department of SurgeryUCSF School of Medicine

FOLLOW

Surgery Websites
  • About the Lab

  • People

  • Research

  • Publications

  • Open Positions

  • Contact Us

  • News & Events

TSI Lab »  Research

Support our Research

A gift to the Transplant and Stem Cell Immunobiology (TSI) Lab will drive clinical advances in treatment of cardiovascular disease, stem cell immunobiology and regenerative medicine.

Make a Gift
level

Research

Space Medicine

UCSF 20170710 Space 466AWith new funding from the National Aeronautics and Space Administration (NASA), the TSI Lab is investigating the vascular biology of “mice from space”, or rather mice that have spent time at the international space station (ISS). This research will provide insight into what physiological effects time in outer space might have on astronauts, with potentially important implications for future longer-term missions, and has the possibility to open the door to fascinating new discoveries that could be used in earth-bound cardiovascular research.

Space AGE - Space Aging Gravity Experiment

Stem Cell Immunobiology

UCSF 20170710 Space 178AStem cell transplantation is a quickly developing area of research with the goal of replacing, regenerating, or reinvigorating injured tissues. Allogeneic stem cells are often rejected by the immune system of the transplant recipient, drastically reducing their potential positive therapeutic effects. Upon the advent of induced pluripotent stem cells (iPS cells), the possibility of creating patient-specific stem cell lines gave hope for a reduced risk of rejection.

It is apparent, however, that large-scale generation of patient-specific iPS cells is not time, cost, or labor effective. Somatic cell nuclear transfer (SCNT) was proposed as a possible alternative to quickly and easily generate patient-specific material, but the TSI Lab recently showed that mismatched mitochondrial proteins found after SCNT are enough to trigger rejection (Deuse et al. 2015). It remains one of the “holy grails” of stem cell transplantation research to find a technique that consistently does not result in rejection.

The TSI Lab is currently pursuing multiple methods to create a so called “off the shelf” stem cell line that could be used in any patient without triggering an immune response. This might be achieved by molecularly modifying currently available stem cell lines to create non-immunogenic stem cell lines. By altering the proteins that cause rejection in the first place, these lines might be able to avoid immune recognition. Alternatively, generating a local hypo-immunogenic environment that could prevent post-transplant rejection without affecting the general immune system would have a myriad of potential applications. Many intriguing research directions are presently emerging at the TSI Lab.

Related Publications

Deuse T, Wang D, Stubbendorff M, Itagaki R, Grabosch A, Greaves LC, Alawi M, Grünewald A, Hu X, Hua X, Velden J, Reichenspurner H, Robbins RC, Jaenisch R, Weissman IL, Schrepfer S 
SCNT-derived ESCs with mismatched mitochondria trigger an immune response in allogeneic hosts. 
Cell stem cell, Jan-8-2015;16(1):33-8.  Epub 2014 Nov 20.
View Abstract | PubMed AbstractPlus

Transplant Immunology

UCSF 20170710 Space 376AOrgan transplantation is often the only clinical option available for treating certain types of cardiovascular disease. While frequently successfully performed, organ transplantation is often accompanied by immune system complications that result in rejection. The TSI Lab is highly motivated toward designing methods to help prevent such rejection, ranging from investigating the immunogenicity of matrix components of bioengineered tissue for transplantation (Conradi et al. 2015), to use of techniques that allow visualization of immune responses after transplantation (Conradi et al. 2011), to identifying novel immunosuppressants for prevention of acute cardiac graft rejection (Deuse et al. 2012). The TSI Lab continues to develop new concepts to identify and prevent immune rejection post-transplantion.

Related Publications

Conradi L, Pahrmann C, Schmidt S, Deuse T, Hansen A, Eder A, Reichenspurner H, Robbins RC, Eschenhagen T, Schrepfer S 
Bioluminescence imaging for assessment of immune responses following implantation of engineered heart tissue (EHT). 
Journal of visualized experiments : JoVE, 2011;[epublish](52).
View Abstract | PubMed AbstractPlus

Conradi L, Schmidt S, Neofytou E, Deuse T, Peters L, Eder A, Hua X, Hansen A, Robbins RC, Beygui RE, Reichenspurner H, Eschenhagen T, Schrepfer S 
Immunobiology of fibrin-based engineered heart tissue. 
Stem cells translational medicine, Jun-2015;4(6):625-31.  Epub 2015 May 6.
View Abstract | PubMed AbstractPlus

Deuse T, Hua X, Taylor V, Stubbendorff M, Baluom M, Chen Y, Park G, Velden J, Streichert T, Reichenspurner H, Robbins RC, Schrepfer S 
Significant reduction of acute cardiac allograft rejection by selective janus kinase-1/3 inhibition using R507 and R545. 
Transplantation, Oct-15-2012;94(7):695-702.
View Abstract | PubMed AbstractPlus

Cardiovascular Disease

UCSF 20170710 Space 411ACardiovascular disease (CD) is responsible for around 30% of all mortalities, making CD the foremost cause of death worldwide. Accordingly, development of cutting edge CD treatment options has become a high priority for researchers. The TSI Lab is focused on generating methods to treat CD from multiple directions, including avenues associated with drug identification and improved transplantation methodology.

Recent TSI Lab CD treatment research has included several clinically relevant discoveries. One area of innovation has been with regard to preventing vascular restenosis, a potentially fatal development which can occur either as a by-product of CD or in response to otherwise positive transplantation treatments. The TSI Lab has identified multiple methods to prevent the progression of restenosis, including through the use of dichloroacetate (Deuse et al. 2014) and by inhibiting ε Protein Kinase C (Deuse et al. 2010) in order to reduce smooth muscle cell proliferation and activation. The TSI Lab continues to pursue new methods to combat CD and its associated medical complications.

Related Publications

Deuse T, Koyanagi T, Erben RG, Hua X, Velden J, Ikeno F, Reichenspurner H, Robbins RC, Mochly-Rosen D, Schrepfer S 
Sustained inhibition of epsilon protein kinase C inhibits vascular restenosis after balloon injury and stenting. 
Circulation, Sep-14-2010;122(11 Suppl):S170-8.
View Abstract | PubMed AbstractPlus
Deuse T, Hua X, Wang D, Maegdefessel L, Heeren J, Scheja L, Bolaños JP, Rakovic A, Spin JM, Stubbendorff M, Ikeno F, Länger F, Zeller T, Schulte-Uentrop L, Stoehr A, Itagaki R, Haddad F, Eschenhagen T, Blankenberg S, Kiefmann R, Reichenspurner H, Velden J, Klein C, Yeung A, Robbins RC, Tsao PS, Schrepfer S 
Dichloroacetate prevents restenosis in preclinical animal models of vessel injury. 
Nature, May-29-2014;509(7502):641-4.  Epub 2014 Apr 20.
View Abstract | PubMed AbstractPlus
 
     
    Site Directory
    • Department of Surgery
    • Web Support Portal
    • Surgery Staff Portal
    • CLINICAL WEBSITES
    • Acute Care Surgery
    • Adult Cardiothoracic Surgery
    • Bariatric Surgery
    • Breast Care Surgery
    • Cardiac Surgery
    • Center for Hernia Repair & Abdominal Wall Reconstruction
    • Center for Limb Preservation and Diabetic Foot
    • Center for Surgery in Older Adults
    • Colorectal Surgery
    • Endocrine Surgery
    • Enhanced Recovery After Surgery (ERAS)
    • Fetal Treatment Center
    • Gastrointestinal Surgery
    • General Surgery
    • Hepatobiliary & Pancreatic Surgery
    • LiverSource
    • Melanoma Surgery
    • Ostomy Education Portal
    • Pediatric Cardiothoracic Surgery
    • Pediatric Surgery
    • Plastic & Reconstructive Surgery
    • Robotic Surgery
    • San Francisco VA Medical Center
    • Surgical Oncology Program
    • Thoracic Oncology Program
    • Thoracic Surgery
    • Transplant Surgery
    • UCSF East Bay Surgery Program
    • Vascular & Endovascular Surgery
    • Zuckerberg San Francisco General
    • EDUCATION AND TRAINING
    • Abdominal Transplant Fellowship
    • Faculty Affairs & Development Portal
    • Medical Student Portal
    • Muriel Steele Society
    • Plastic Surgery Residency
    • Resident Portal
    • Resident Research
    • Surgical & Critical Care NP Fellowship
    • Surgery Education Portal
    • Surgery Research Portal
    • Surgical Skills Center
    • Thoracic Surgery Residency
    • T32 Surgical Oncology
    • T32 Research Training in Transplant Surgery
    • UCSF-East Bay General Surgery Residency
    • Vascular Surgery Integrated Residency
    • RESEARCH WEBSITES
    • Atherosclerosis Research Lab
    • Biostatistics Core
    • Cardiothoracic Translational Research Lab
    • Cardiac Biomechanics Lab
    • Center for Global Surgery and Health Equity
    • Center for Maternal-Fetal Precision Medicine
    • Center for Mindfulness in Surgery
    • Chang Laboratory for Liver Tissue Engineering
    • Conte Lab
    • Endocrine Neoplasia Research Lab
    • Immunogenetics & Transplantation Lab
    • Kornblith Lab
    • Kratz Lab
    • Lobular Breast Cancer Research Program
    • MacKenzie Lab
    • Nijagal Lab
    • Pediatric Device Consortium
    • Pediatric Surgery Lab
    • Pomerantz Lab
    • San Francisco Wraparound Project
    • Sarwal Lab
    • Surgical Innovations
    • Warren Lab in Surgical Oncology
    • Tang Lab
    • Thoracic Oncology Lab
    • Transplantation Research Lab
    • TSI Lab
    • Wang Lab
    • Weaver Lab
    • Willenbring Lab
    • RESOURCES
    • Scientific Publications Office
      © 2023 The Regents of the University of California. 
      Terms of Use | Report a Problem
      Site Developer: Jason Powers; Web Manager, Rob Mayfield; Engineer, Digital Strategies

      FOLLOW

      X